S&P 500   4,586.95 (+0.77%)
DOW   35,667.37 (+0.50%)
QQQ   383.47 (+0.91%)
AAPL   152.56 (+2.49%)
MSFT   323.34 (+0.05%)
FB   315.52 (+1.06%)
GOOGL   2,921.90 (-0.08%)
TSLA   1,072.58 (+3.35%)
AMZN   3,475.73 (+2.45%)
NVDA   247.57 (+1.25%)
BABA   169.97 (+0.44%)
NIO   40.49 (+3.00%)
CGC   12.95 (+1.33%)
GE   104.30 (+0.43%)
AMD   121.03 (-1.02%)
MU   69.37 (+1.66%)
T   25.62 (+2.23%)
F   16.87 (+8.77%)
ACB   6.90 (+0.88%)
DIS   170.15 (+0.35%)
PFE   43.16 (+0.44%)
BA   207.10 (+0.24%)
AMC   35.16 (+1.15%)
S&P 500   4,586.95 (+0.77%)
DOW   35,667.37 (+0.50%)
QQQ   383.47 (+0.91%)
AAPL   152.56 (+2.49%)
MSFT   323.34 (+0.05%)
FB   315.52 (+1.06%)
GOOGL   2,921.90 (-0.08%)
TSLA   1,072.58 (+3.35%)
AMZN   3,475.73 (+2.45%)
NVDA   247.57 (+1.25%)
BABA   169.97 (+0.44%)
NIO   40.49 (+3.00%)
CGC   12.95 (+1.33%)
GE   104.30 (+0.43%)
AMD   121.03 (-1.02%)
MU   69.37 (+1.66%)
T   25.62 (+2.23%)
F   16.87 (+8.77%)
ACB   6.90 (+0.88%)
DIS   170.15 (+0.35%)
PFE   43.16 (+0.44%)
BA   207.10 (+0.24%)
AMC   35.16 (+1.15%)
S&P 500   4,586.95 (+0.77%)
DOW   35,667.37 (+0.50%)
QQQ   383.47 (+0.91%)
AAPL   152.56 (+2.49%)
MSFT   323.34 (+0.05%)
FB   315.52 (+1.06%)
GOOGL   2,921.90 (-0.08%)
TSLA   1,072.58 (+3.35%)
AMZN   3,475.73 (+2.45%)
NVDA   247.57 (+1.25%)
BABA   169.97 (+0.44%)
NIO   40.49 (+3.00%)
CGC   12.95 (+1.33%)
GE   104.30 (+0.43%)
AMD   121.03 (-1.02%)
MU   69.37 (+1.66%)
T   25.62 (+2.23%)
F   16.87 (+8.77%)
ACB   6.90 (+0.88%)
DIS   170.15 (+0.35%)
PFE   43.16 (+0.44%)
BA   207.10 (+0.24%)
AMC   35.16 (+1.15%)
S&P 500   4,586.95 (+0.77%)
DOW   35,667.37 (+0.50%)
QQQ   383.47 (+0.91%)
AAPL   152.56 (+2.49%)
MSFT   323.34 (+0.05%)
FB   315.52 (+1.06%)
GOOGL   2,921.90 (-0.08%)
TSLA   1,072.58 (+3.35%)
AMZN   3,475.73 (+2.45%)
NVDA   247.57 (+1.25%)
BABA   169.97 (+0.44%)
NIO   40.49 (+3.00%)
CGC   12.95 (+1.33%)
GE   104.30 (+0.43%)
AMD   121.03 (-1.02%)
MU   69.37 (+1.66%)
T   25.62 (+2.23%)
F   16.87 (+8.77%)
ACB   6.90 (+0.88%)
DIS   170.15 (+0.35%)
PFE   43.16 (+0.44%)
BA   207.10 (+0.24%)
AMC   35.16 (+1.15%)
NASDAQ:CRXT

Clarus Therapeutics Stock Forecast, Price & News

$4.09
-0.12 (-2.85 %)
(As of 10/28/2021 12:55 PM ET)
Add
Compare
Today's Range
$4.00
$4.13
50-Day Range
N/A
52-Week Range
$3.43
$31.24
Volume
1,304 shs
Average Volume
585,380 shs
Market Capitalization
$88.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive CRXT News and Ratings via Email

Sign-up to receive the latest news and ratings for Clarus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Clarus Therapeutics logo

About Clarus Therapeutics

Clarus Therapeutics Inc. is a specialty pharmaceutical company which provide solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women. The Company's commercial product includes JATENZO(R). Clarus Therapeutics Inc., formerly known as Blue Water Acquisition Corp., is based in NORTHBROOK, Ill.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRXT
Web
N/A
Employees
2
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$2.35 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$88.86 million
Next Earnings Date
N/A
Fiscal Year End
December 31
Optionable
Not Optionable

MarketRank

Overall MarketRank

2.36 out of 5 stars

Medical Sector

214th out of 1,372 stocks

Biological Products, Except Diagnostic Industry

31st out of 197 stocks

Analyst Opinion: 4.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Clarus Therapeutics (NASDAQ:CRXT) Frequently Asked Questions

Is Clarus Therapeutics a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Clarus Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Clarus Therapeutics stock.
View analyst ratings for Clarus Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Clarus Therapeutics?

Wall Street analysts have given Clarus Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Clarus Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for CRXT?

7 Wall Street analysts have issued 1-year target prices for Clarus Therapeutics' shares. Their forecasts range from $10.00 to $20.00. On average, they anticipate Clarus Therapeutics' stock price to reach $12.43 in the next year. This suggests a possible upside of 203.9% from the stock's current price.
View analysts' price targets for Clarus Therapeutics
or view top-rated stocks among Wall Street analysts.

What is Clarus Therapeutics' stock symbol?

Clarus Therapeutics trades on the NASDAQ under the ticker symbol "CRXT."

How do I buy shares of Clarus Therapeutics?

Shares of CRXT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Clarus Therapeutics' stock price today?

One share of CRXT stock can currently be purchased for approximately $4.09.

How much money does Clarus Therapeutics make?

Clarus Therapeutics has a market capitalization of $88.86 million.

How many employees does Clarus Therapeutics have?

Clarus Therapeutics employs 2 workers across the globe.

Where are Clarus Therapeutics' headquarters?

Clarus Therapeutics is headquartered at 15 E. PUTNAM AVENUE SUITE 363, GREENWICH CT, 06830.

How can I contact Clarus Therapeutics?

Clarus Therapeutics' mailing address is 15 E. PUTNAM AVENUE SUITE 363, GREENWICH CT, 06830. The company can be reached via phone at 646-303-0737.


This page was last updated on 10/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.